Analysts for Paradigm Capital and Canaccord Genuity in new reports said that Profound Medical’s (NASDAQ:PRFMF; TSX:PRN) inaugural analyst day illustrated a strong case for adoption of the company’s TULSA-PRO device for...
OPKO Health (NASDAQ:OPK) reported additional results from its Phase 2 dose escalation trial of OPK-88003, a once-weekly oxyntomodulin for the treatment of Type 2 diabetes and obesity. OPK-88003 is a dual GLP-1/glucagon...
KemPharm (NASDAQ:KMPH) met with the FDA to discuss the NDA for KP415, its attention deficit hyperactivity disorder (ADHD) drug candidate. KP415 consists KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated...
GlycoMimetics (NASDAQ:GLYC) plans to test GMI-1359, a dual function antagonist, in breast cancer patients whose tumors have spread to bone. GMI-1359 targets both E-selectin and CXCR4, which are involved in tumor...
Eiger BioPharmaceuticals (NASDAQ:EIGR) presented positive post-treatment results from its Phase 2 trial of lambda interferon monotherapy (LIMT) in patients with chronic hepatitis D virus (HDV). The study enrolled 33...
TRACON Pharmaceuticals (NASDAQ:TCON) terminated for futility its Phase 3 TAPPAS trial, evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma, based on a recommendation of...
Hancock Jaffe (NASDAQ:HJLI) has implanted VenoValves in four patients with severe, chronic venous insufficiency (CVI) as part of its first-in-human study of the device. CVI occurs when the valves in the veins of the leg...
Otonomy (NASDAQ:OTIC) initiated a Phase 1/2 trial of OTO-313, a novel formulation of gacyclidine, for the treatment of tinnitus. Patients with tinnitus experience noise or ringing in their ears. Otonomy notes that some...
ContraVir Pharmaceuticals (NASDAQ:CTRV) will present a poster on a Phase 1 single ascending dose study of its drug candidate, CRV431, at the International Liver Congress, taking place in Vienna, Austria from April 10-to...
Q BioMed (OTCQB:QBIO) has discovered two novel biomarkers for pediatric nonverbal autism (PNA) in a subset of children with autism spectrum disorder (ASD). Children with PNA never develop the ability to speak, or begin...